Table 1.

Demographics and treatment-related characteristics

	Entire Cohort (n=1,161)	Gained Weight (n=649)	Lost Weight (n=512)	p-value
Preoperative weight (lbs)*	155 (92 – 340)	157.7 (92 – 340)	167.8 (97.5 – 322)	<0.001
Net weight change (lbs)*	--	8.2 (0.1 – 49.0)	−8.7 (−81.0 – −0.1)	<0.001
Preoperative BMI (kg/m2)*	26.6 (15.8 – 58.9)	27.1 (15.8 – 58.4)	29.0 (18.4 – 58.9)	<0.001
Age (years)*	56.6 (27.0 – 85.9)	55.5 (27.2 – 85.9)	58.0 (27.0 – 82.3)	<0.001
Race
White	1,042 (89.8%)	582 (89.8%)	460 (89.8%)	0.999
Non-white	118 (10.2%)	66 (10.2%)	52 (10.2%)
Surgery
Mastectomy	237 (20.4%)	137 (21.1%)	100 (19.5%)	0.556
Lumpectomy	924 (79.6%)	512 (78.9%)	412 (0.5%)
Nodal surgery
ALND	326 (28.1%)	192 (30.0%)	134 (26.2%)	0.304
SLNB	782 (67.4%)	425 (65.5%)	357 (69.7%)
None	53 (4.6%)	32 (4.9%)	21 (4.1%)
Lymph nodes sampled**	2 (0 – 43)	3 (0 – 41)	2 (1 – 43)	0.395
Lymph nodes malignant**	0 (0 – 39)	0 (0 – 39)	0 (0 – 32)	0.834
Breast cancer stage
I	686 (59.1%)	388 (59.8%)	298 (58.2%)
II	337 (29.0%)	193 (29.7%)	144 (28.1%)
III	134 (11.5%)	68 (10.5%)	66 (12.9%)	0.405
Unknown	4 (0.3%)	--	4 (0.8%)
RLNR	372 (32.0%)	209 (2.2%)	163 (31.8%)	0.944
Neoadjuvant chemotherapy	150 (12.9%)	89 (13.7%)	61 (11.9%)	0.520
Adjuvant chemotherapy	456 (39.3%)	255 (39.3%)	201 (39.3%)	0.999
Adjuvant hormonal therapy	932 (80.3%)	525 (80.9%)	407 (79.5%)	0.602
Maximum follow-up (months since baseline)*	49.1 (1.2, 178.2)	48.7 (1.2, 151.7)	49.5 (1.4, 178.2)	0.630
Developed BCRL	92 (7.9%)	43 (6.6%)	49 (9.6%)	0.083
Time to onset of BCRL (months since surgery)**	18.5 (3.0 – 115.0)	20.7 (3.0 – 110.2)	16.2 (3.4 – 115.0)	0.684

^*Mean or

^**median with (range) is shown.

p-value compares variables between those who gained weight vs. those who lost weight.

Abbreviations: body mass index (BMI); axillary lymph node dissection (ALND); sentinel lymph node biopsy (SLNB); regional lymph node radiation (RLNR); breast cancer-related lymphedema (BCRL).